INTRA CELLULAR THERAPIES INC's ticker is ITCI and the CUSIP is 46116X101. A total of 133 filers reported holding INTRA CELLULAR THERAPIES INC in Q1 2018. The put-call ratio across all filers is 0.53 and the average weighting 0.1%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2018 | $4,069,000 | +22.8% | 187,500 | 0.0% | 0.15% | +15.7% |
| Q2 2018 | $3,313,000 | -16.1% | 187,500 | 0.0% | 0.13% | -24.4% |
| Q1 2018 | $3,947,000 | +45.4% | 187,500 | 0.0% | 0.17% | +36.6% |
| Q4 2017 | $2,715,000 | -8.2% | 187,500 | 0.0% | 0.12% | -10.2% |
| Q3 2017 | $2,959,000 | +27.1% | 187,500 | 0.0% | 0.14% | +16.1% |
| Q2 2017 | $2,329,000 | -24.6% | 187,500 | -1.3% | 0.12% | -33.7% |
| Q1 2017 | $3,088,000 | +7.7% | 190,000 | 0.0% | 0.18% | -7.3% |
| Q4 2016 | $2,867,000 | -1.0% | 190,000 | 0.0% | 0.19% | +5.5% |
| Q3 2016 | $2,896,000 | -60.7% | 190,000 | 0.0% | 0.18% | -66.7% |
| Q2 2016 | $7,376,000 | +41.5% | 190,000 | +1.3% | 0.55% | +24.9% |
| Q1 2016 | $5,213,000 | -46.2% | 187,500 | +4.2% | 0.44% | -40.5% |
| Q4 2015 | $9,682,000 | +34.3% | 180,000 | 0.0% | 0.73% | +25.5% |
| Q3 2015 | $7,207,000 | – | 180,000 | – | 0.58% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| TANG CAPITAL MANAGEMENT LLC | 700,000 | $42,833,000 | 8.57% |
| SILVERARC CAPITAL MANAGEMENT, LLC | 308,819 | $18,897,000 | 7.82% |
| Vahanian & Associates Financial Planning Inc. | 45,533 | $2,786,000 | 6.44% |
| DCF Advisers, LLC | 238,500 | $14,594,000 | 6.39% |
| INTERNATIONAL BIOTECHNOLOGY TRUST PLC | 50,956 | $20,930,000 | 4.72% |
| SUVRETTA CAPITAL MANAGEMENT, LLC | 1,531,923 | $93,738,000 | 2.86% |
| Nicholas Investment Partners, LP | 562,373 | $34,412,000 | 2.45% |
| Bellevue Group AG | 3,429,619 | $209,859,000 | 2.44% |
| WASATCH ADVISORS LP | 7,477,868 | $457,571,000 | 2.25% |
| Quantum Private Wealth, LLC | 73,772 | $4,514,000 | 1.95% |